Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Regulatory News (PRTC)

Share Price Information for PureTech (PRTC)

Share Price is delayed by 15 minutes
Get Live Data
123.00    -0.80 (-0.65%)
Bid:
122.60
Ask:
123.00
Spread: 0.40 (0.326%)
Market Cap: £299.40m
PRTC Live PriceLast checked at - London Stock Exchange

Intraday PureTech Share Chart

Form 8.5 (EPT/RI)

10 Oct 2022 09:18

RNS Number : 3204C
Liberum Capital Limited
10 October 2022
 

 

FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Liberum Capital Limited

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

PureTech Health plc

(c) Name of the party to the offer with which exempt principal trader is connected:

PureTech Health plc

(d) Date dealing undertaken:

07th October 2022

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?

If it is a cash offer or possible cash offer, state "N/A"

No

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

 

ORD 25p

 

 

Purchase

 

14,664

 

2.21

 

2.2

 

ORD 25p

 

 

Sale

 

14,664

 

2.21

 

2.2

 

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

 

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

 

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

 

Date of disclosure:

10th October 2022

 

Contact name:

Kristina Kapur

Telephone number:

020 3100 2034

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service. 

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FERGIBDGLBBDGDG
Date   Source Headline
8th Jun 20227:00 amRNSTransaction in Own Shares
7th Jun 20227:00 amRNSTransaction in Own Shares
6th Jun 20225:00 pmRNSTransaction in Own Shares
6th Jun 20227:05 amRNSAkili Adds Another Life Sciences Vet to C-Suite
6th Jun 20227:00 amRNSGLS Data at ADA: Metabolic Benefits & Gut Bacteria
1st Jun 202212:00 pmRNSPRTC to Present at Jefferies Healthcare Conference
1st Jun 20227:00 amRNSTotal Voting Rights
1st Jun 20227:00 amRNSTransaction in Own Shares
31st May 20227:00 amRNSTransaction in Own Shares
30th May 20227:00 amRNSTransaction in Own Shares
27th May 20227:00 amRNSTransaction in Own Shares
26th May 202212:05 pmRNSAkili & Roblox (NYSE:RBLX) Partner on EndeavorRx
26th May 20227:00 amRNSTransaction in Own Shares
25th May 20227:00 amRNSTransaction in Own Shares
24th May 20228:05 amRNSPRTC's Vedanta Presents Data at DDW Annual Meeting
24th May 20227:00 amRNSTransaction in Own Shares
23rd May 20227:00 amRNSTransaction in Own Shares
20th May 20227:00 amRNSTransaction in Own Shares
19th May 20227:00 amRNSPDMR Notification RSU Vesting
19th May 20227:00 amRNSTransaction in Own Shares
18th May 20227:00 amRNSTransaction in Own Shares
17th May 202212:00 pmRNSPRTC to Present at UBS Healthcare Conference
17th May 20227:00 amRNSTransaction in Own Shares
16th May 20222:30 pmRNSPRTC Presents LYT-100 Data at ATS Conference
16th May 20227:00 amRNSTransaction in Own Shares
13th May 20227:00 amRNSTransaction in Own Shares
12th May 20227:00 amRNSTransaction in Own Shares
11th May 20227:00 amRNSTransaction in Own Shares
10th May 20227:00 amRNSTransaction in Own Shares
9th May 20227:00 amRNSPRTC Share Buyback Programme Commences Purchases
5th May 20227:00 amRNSPRTC Announces Share Buyback Programme Up to $50M
4th May 202211:35 amRNSGelesis Presents GS200 Weight Loss Data at ECO
3rd May 20227:00 amRNSTotal Voting Rights
29th Apr 202211:05 amRNSGelesis Data: Therapeutic Shows Gut Health Benefit
26th Apr 20227:00 amRNSPRTC Final Results & Publication of Annual Report
13th Apr 20224:44 pmRNSPRTC's Vedanta Publishes VE303 Data
12th Apr 202212:05 pmRNSAkili Depression Data Published in AJP
12th Apr 20227:00 amRNSGlyph: 20x Oral Bioavailability of Buprenorphine
7th Apr 20227:00 amRNSNotice of Results
1st Apr 20227:00 amRNSTotal Voting Rights
24th Mar 20227:00 amRNSPRTC Appoints Merck Vet to BOD & Audit Committee
17th Mar 20221:05 pmRNSAkili Adds Gaming Vet as Chief Product Officer
16th Mar 202210:35 amRNSGelesis: Record-Breaking Plenity Prescriptions
8th Mar 202212:05 pmRNSAkili Named to World's Most Innovative Companies
18th Feb 20224:30 pmRNSHolding(s) in Company
17th Feb 202212:05 pmRNSAkili Data: Enhanced Brain Activity in Kids w/ADHD
15th Feb 20227:00 amRNSPRTC's Akili Files Registration Statement on S-4
10th Feb 202212:00 pmRNSPRTC to Present at Leerink Healthcare Conference
4th Feb 20227:00 amRNSPDMR DEALING - PURCHASE OF SHARES
31st Jan 202211:50 amRNSPRTC's Gelesis Launches Plenity Media Campaign

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.